The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | G | Genito urinary system and sex hormones | |
2 | G03 | Sex hormones and modulators of the genital system | |
3 | G03X | Other sex hormones and modulators of the genital system |
Code | Title | |
---|---|---|
G03XA | Antigonadotropins and similar agents | |
G03XB | Antiprogestogens | |
G03XC | Selective estrogen receptor modulators | |
G03XX | Other sex hormones and modulators of the genital system |
Active Ingredient | Description | |
---|---|---|
Bazedoxifene |
|
|
Danazol |
Danazol is a synthetic steroid derived from ethisterone an is indicated for the treatment of endometriosis and benign fibrocystic breast disease. |
|
Mifepristone |
Mifepristone is a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors. |
|
Ospemifene |
Ospemifene and its major metabolite have an oestrogen like effect in the vagina increasing the cellular maturation and mucification of the vaginal epithelium. Ospemifene’s biological actions are mediated through the binding of ospemifene and its major metabolite to oestrogen receptors leading to activation of some oestrogenic pathways (agonism) and blockade of other (antagonism). |
|
Prasterone |
Prasterone, i.e. dehydroepiandrosterone (DHEA), biochemically and biologically identical to the endogenous human DHEA, is a precursor steroid which is inactive by itself and it is converted into oestrogens and androgens. Intrarosa is thus different from the oestrogens preparations since it delivers also androgen metabolites. |
|
Raloxifene |
As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues. |
|
Ulipristal |
Ulipristal is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. When used for emergency contraception the mechanism of action is inhibition or delay of ovulation via suppression of the luteinising hormone (LH) surge. Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days. |
Title | Information Source | Document Type | |
---|---|---|---|
ANARGIL Capsule, hard | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
CONBRIZA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ESMYA Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
EVISTA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
EVISTA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
MEDABON CO Tablet, Vaginal tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
MIFEGYNE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
OPTRUMA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ORILISSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
SENSHIO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |